An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study

Inclusion Criteria:

• Participant is treated with bevacizumab at the end of the Roche/Genentech sponsoredparent trial and continues to have benefit as judged by the investigator
• Eligible for continuation of bevacizumab treatment at the end of a parent trial,according to parent trial protocol
• Able to comply with this extension study protocol (MO25757)

Exclusion Criteria:

• Evidence of disease progression assessed according to parent trial protocol during thescreening phase for this extension study
• Evidence of any adverse event potentially attributable to bevacizumab, for which thelocal label recommends permanent discontinuation
• A treatment interruption with bevacizumab of more than 42 days since the lastadministration of bevacizumab in the parent trial
• Evidence of any other disease that would put the participant at high risk fortreatment-related complications